{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fabry+Disease",
    "query": {
      "condition": "Fabry Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 97,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fabry+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:49:46.322Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00343577",
      "title": "Antiproteinuric Agents and Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease",
        "Proteinuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "14 Years to 95 Years"
      },
      "enrollment_count": 12,
      "start_date": "2001-01",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343577"
    },
    {
      "nct_id": "NCT04552691",
      "title": "Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Pegunigalsidase Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04552691"
    },
    {
      "nct_id": "NCT01839526",
      "title": "A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Iohexol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "5 Years to 25 Years · Male only"
      },
      "enrollment_count": 39,
      "start_date": "2013-05",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2020-12-16",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Decatur, Georgia • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01839526"
    },
    {
      "nct_id": "NCT04252066",
      "title": "A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "migalastat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-18",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04252066"
    },
    {
      "nct_id": "NCT02795676",
      "title": "Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "PRX-102 (pegunigalsidase alfa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "agalsidase beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protalix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 78,
      "start_date": "2016-06",
      "completion_date": "2022-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795676"
    },
    {
      "nct_id": "NCT03500094",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Migalastat HCl 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2018-09-27",
      "completion_date": "2021-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 7,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03500094"
    },
    {
      "nct_id": "NCT00701415",
      "title": "A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Agalsidase beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "5 Years to 18 Years · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2008-09",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-06-29",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Cincinnati, Ohio • Seattle, Washington",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00701415"
    },
    {
      "nct_id": "NCT00068107",
      "title": "Dosing Study of Replagal in Patients With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Replagal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 13,
      "start_date": "2003-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068107"
    },
    {
      "nct_id": "NCT00357786",
      "title": "An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Replagal agalsidase alfa",
          "type": "DRUG"
        },
        {
          "name": "Replagal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "39 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "39 Years to 45 Years · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-08-17",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357786"
    },
    {
      "nct_id": "NCT03289065",
      "title": "Fabry Outcome Survey (FOS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4000,
      "start_date": "2001-04-01",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-11-16",
      "last_synced_at": "2026-05-22T04:49:46.322Z",
      "location_count": 1,
      "location_summary": "Lexington, Massachusetts",
      "locations": [
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03289065"
    }
  ]
}